The Role of Clusterin in Amyloid-β–Associated Neurodegeneration
Open accessAbstract
IMPORTANCE: Converging evidence indicates that clusterin, a chaperone glycoprotein, influences Alzheimer disease neurodegeneration. However, the precise role of clusterin in Alzheimer disease pathogenesis is still not well understood. OBJECTIVE: To elucidate the relationship between clusterin, amyloid-β (Aβ), phosphorylated tau (p-tau), and the rate of brain atrophy over time among nondemented older individuals. DESIGN, SETTING, AND PARTICIPANTS: This longitudinal cohort included cognitively normal older participants and individuals with mild cognitive impairment assessed with baseline lumbar puncture and longitudinal structural magnetic resonance imaging. We examined 241 nondemented older individuals from research centers across the United States and Canada (91 participants with a Clinical Dementia Rating score of 0 and 150 individuals with a Clinical Dementia Rating score of 0.5). MAIN OUTCOMES AND MEASURES: Using linear mixed-effects models, we investigated interactions between cerebrospinal fluid (CSF) clusterin, CSF Aβ1-42, and CSF p-tau at threonine 181 (p-tau181p) on the atrophy rate of the entorhinal cortex and hippocampus. RESULTS: Across all participants, we found a significant interaction between CSF clusterin and CSF Aβ1-42 on the entorhinal cortex atrophy rate but not on the hippocampal atrophy rate. Cerebrospinal fluid clusterin was associated with the entorhinal cortex atrophy rate among CSF Aβ1-42-positive individuals but not among CSF Aβ1-42-negative individuals. In secondary analyses, we found significant interactions between CSF Aβ1-42 and CSF clusterin, as well as CSF Aβ1-42 and CSF p-tau181p, on the entorhinal cortex atrophy rate. We found similar results in subgroup analyses within the mild cognitive impairment and cognitively normal cohorts. CONCLUSIONS AND RELEVANCE: In nondemented older individuals, Aβ-associated volume loss occurs in the presence of elevated clusterin. The effect of clusterin on Aβ-associated brain atrophy is not confounded or explained by p-tau. These findings implicate a potentially important role for clusterin in the earliest stages of the Alzheimer disease neurodegenerative process and suggest independent effects of clusterin and p-tau on Aβ-associated volume loss.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Elevated CSF clusterin together with elevated amyloid-beta is associated with greater entorhinal atrophy.
“Increased cerebrospinal fluid (CSF) CLU levels combined with increased amyloid-beta (Aβ) levels were associated with increased entorhinal atrophy (Desikan, et al., 2014)”
From A potential endophenotype for Alzheimer's disease: cerebrospinal fluid clusterin (2016) · cites this paper as Desikan, et al., 2014
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · see citing works
Desikan, R. S., Ségonne, F., Fischl, B., Quinn, B. T., Dickerson, B. C., Blacker, D., Buckner, R. L., Dale, A. M., Maguire, R. P., Hyman, B. T., et al. (2006) · NeuroImage · doi:10.1016/j.neuroimage.2006.01.021 · Cited by 13,324 · see citing works
Self-citationThe Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882 · see citing works
Fischl, B., Salat, D. H., Busa, E., Albert, M., Dieterich, M., Haselgrove, C., van der Kouwe, A., Killiany, R., Kennedy, D., Klaveness, S., et al. (2002) · Neuron · doi:10.1016/s0896-6273(02)00569-x · Cited by 8,610 · see citing works
Self-citationLambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506 · see citing works
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065 · see citing works
Self-citationBobinski, M., de Leon, M. J., Wegiel, J., DeSanti, S., Convit, A., Saint Louis, L. A., Rusinek, H., & Wisniewski✠, H. M. (1999) · Neuroscience · doi:10.1016/s0306-4522(99)00476-5 · Cited by 455 · see citing works
Thambisetty, M., Simmons, A., Velayudhan, L., Hye, A., Campbell, J., Zhang, Y., Wahlund, L.-O., Westman, E., Kinsey, A., Güntert, A., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.78 · Cited by 405 · see citing works
DeMattos, R. B., O'dell, M. A., Parsadanian, M., Taylor, J. W., Harmony, J. A. K., Bales, K. R., Paul, S. M., Aronow, B. J., & Holtzman, D. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162228299 · Cited by 359 · see citing works
Clusterin: A forgotten player in Alzheimer's disease
Nuutinen, T., Suuronen, T., Kauppinen, A., & Salminen, A. (2009) · Brain Research Reviews · doi:10.1016/j.brainresrev.2009.05.007 · Cited by 267 · see citing works
Structural MRI biomarkers for preclinical and mild Alzheimer's disease
Fennema‐Notestine, C., Hagler, D. J., McEvoy, L. K., Fleisher, A. S., Wu, E. H., Karow, D. S., & Dale, A. M. (2009) · Human Brain Mapping · doi:10.1002/hbm.20744 · Cited by 233 · see citing works
Self-citationClusterin regulates β-amyloid toxicity via Dickkopf-1-driven induction of the wnt–PCP–JNK pathway
Killick, R., Ribe, E. M., Al-Shawi, R., Malik, B., Hooper, C., Fernandes, C., Dobson, R., Nolan, P. M., Lourdusamy, A., Furney, S., et al. (2014) · Molecular Psychiatry · doi:10.1038/mp.2012.163 · Cited by 222 · see citing works
Plasma clusterin and the risk of Alzheimer disease
Schrijvers, E. M. C. (2011) · JAMA · doi:10.1001/jama.2011.381 · Cited by 220 · see citing works
Distribution of clusterin in Alzheimer brain tissue
McGeer, P. L., Kawamata, T., & Walker, D. G. (1992) · Brain Research · doi:10.1016/0006-8993(92)90071-g · Cited by 212 · see citing works
Freeman, S. H., Kandel, R., Cruz, L., Rozkalne, A., Newell, K. L., Frosch, M. P., Hedley‐Whyte, E. T., Locascio, J. J., Lipsitz, L. A., & Hyman, B. T. (2008) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31818fc72f · Cited by 212 · see citing works
Self-citationFluid Biomarkers in Alzheimer Disease
Blennow, K., Zetterberg, H., & Fagan, A. M. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006221 · Cited by 208 · see citing works
Self-citationThe Role of Clusterin in Alzheimer’s Disease: Pathways, Pathogenesis, and Therapy
Yu, J.-T., & Tan, L. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8237-1 · Cited by 174 · see citing works
Lidström, A.-M., Bogdanović, N., Hesse, C., Volkmann, I., Davidsson, P., & Blennow, K. (1998) · Experimental Neurology · doi:10.1006/exnr.1998.6892 · Cited by 163 · see citing works
Self-citationThambisetty, M., An, Y., Kinsey, A. M., Koka, D., Saleem, M., Güntert, A., Kraut, M. A., Ferrucci, L., Davatzikos, C. A., Lovestone, S., et al. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2011.07.056 · Cited by 148 · see citing works
Amyloid-β–Associated Clinical Decline Occurs Only in the Presence of Elevated P-tau
Desikan, R. S., McEvoy, L. K., Thompson, W. K., Holland, D., Brewer, J. B., Aisen, P. S. S., Sperling, R. A., Dale, A. M., & Initiative, A. D. N. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.3354 · Cited by 135 · see citing works
Self-citationAmyloid-β associated volume loss occurs only in the presence of phospho-tau
Desikan, R., McEvoy, L., Thompson, W., Holland, D., Roddey, J., Blennow, K., Aisen, P., Brewer, J., Hyman, B., & Dale, A. (2011) · Annals of Neurology · doi:10.1002/ana.22509 · Cited by 123 · see citing works
Self-citationNonlinear registration of longitudinal images and measurement of change in regions of interest
Holland, D., & Dale, A. M. (2011) · Medical Image Analysis · doi:10.1016/j.media.2011.02.005 · Cited by 114 · see citing works
Self-citationNilselid, A.-M., Davidsson, P., Nägga, K., Andreasen, N., Fredman, P., & Blennow, K. (2006) · Neurochemistry International · doi:10.1016/j.neuint.2005.12.005 · Cited by 104 · see citing works
Self-citationUnbiased comparison of sample size estimates from longitudinal structural measures in ADNI
Holland, D., McEvoy, L. K., Dale, A. M., & Initiative, T. A. D. N. (2011) · Human Brain Mapping · doi:10.1002/hbm.21386 · Cited by 83 · see citing works
Self-citationAltered Gene Expression in Alzheimer's Disease Brain Tissue
May, P. C., Johnson, S. A., Poirier, J., Lampert-Etchells, M., & Finch, C. E. (1989) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100029796 · Cited by 73 · see citing works
Toward a multifactorial model of Alzheimer disease
Storandt, M., Head, D. M., Fagan, A. M., Holtzman, D. M., & Morris, J. C. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.11.029 · Cited by 53 · see citing works
Initiative, A. D. N., Stricker, N. H., Dodge, H. H., Dowling, N. M., Han, S. D., Erosheva, E. A., & Jagust, W. (2012) · Brain Imaging and Behavior · doi:10.1007/s11682-012-9171-6 · Cited by 53 · see citing works
Desikan, R. S., McEvoy, L. K., Holland, D., Thompson, W., Brewer, J. B., Aisen, P. S. S., Andreassen, O. A., Hyman, B. T., Sperling, R. A., Dale, A. M., et al. (2012) · American Journal of Neuroradiology · doi:10.3174/ajnr.a3267 · Cited by 18 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Glial activation and inflammation along the Alzheimer’s disease continuum
Nordengen, K., Kirsebom, B.-E., Henjum, K., Selnes, P., Gísladóttir, B., Wettergreen, M., Torsetnes, S. B., Grøntvedt, G. R., Waterloo, K. K., Aarsland, D., et al. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1399-2 · Cited by 274 · see citing works
Magnetic resonance imaging in Alzheimer’s disease neuroimaging initiative 2
Jack, C. R., Barnes, J., Bernstein, M. A., Borowski, B. J., Brewer, J., Clegg, S., Dale, A. M., Carmichael, O., Ching, C., DeCarli, C., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.05.002 · Cited by 220 · see citing works
Self-citationSteele, N. Z. R., Carr, J. S., Bonham, L. W., Geier, E. G., Damotte, V., Miller, Z. A., Desikan, R. S., Boehme, K. L., Mukherjee, S., Crane, P. K., et al. (2017) · PLOS Medicine · doi:10.1371/journal.pmed.1002272 · Cited by 91 · see citing works
Self-citationA potential endophenotype for Alzheimer's disease: cerebrospinal fluid clusterin
Deming, Y., Xia, J., Cai, Y., Lord, J., Holmans, P., Bertelsen, S., Holtzman, D., Morris, J. C., Bales, K., Pickering, E. H., et al. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.09.009 · Cited by 66 · see citing works
Katsumata, Y., Nelson, P. T., Estus, S., & Fardo, D. W. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.10.017 · Cited by 30 · see citing works
- Authors
- Desikan, R. S., Thompson, W. K., Holland, D., Hess, C. P., Brewer, J. B., Zetterberg, H., Blennow, K., Andreassen, O. A., McEvoy, L. K., Hyman, B. T., & Dale, A. M.
- Affiliations
- University of California San Diego (US)
- University of California, San Francisco (US)
- National Hospital for Neurology and Neurosurgery (GB)
- University of Gothenburg (SE)
- Oslo University Hospital (NO)
- Massachusetts General Hospital (US)
- Corresponding author
- Desikan, Rahul S.
- ORCID
- Venue
- JAMA Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2014-02-01
- Volume
- 71
- Issue
- 2
- Pages
- 180
- ISSN
- 2168-6149 (ISSN-L)
- PMC
- PMC4118752
- OpenAlex
- W2167538572
- Cited by
- 79
- References
- 28
- Citations by year
- 2026: 1 · 2025: 6 · 2024: 2 · 2023: 3 · 2022: 3 · 2021: 5 · 2020: 10 · 2019: 4 · 2018: 9 · 2017: 6 · 2016: 9 · 2015: 12 · 2014: 9
- FWCI
- 7.11
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- JAMA Neurology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- NORA - Norwegian Open Research Archives (submittedVersion, other-oa)
- Funders
- Alzheimer's Association (U01 AG024904)
- Alzheimer's Disease Neuroimaging Initiative (U01AG024904, AG024904)
- Norges Forskningsråd
- National Institutes of Health (5u01ag024904-10, U01-AG024904, AG024904)
- Canadian Institutes of Health Research
- National Institute on Aging (U01-AG-024904, P30AG010129, R01AG031224, P50AG005131, K01AG030514, K01AG029218, U19AG024904)
- National Institute of Neurological Disorders and Stroke (K02NS067427)
- National Institute of Biomedical Imaging and Bioengineering (T32EB005970)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Oncology › Clusterin in disease pathology
- Keywords
- clusterin, amyloid-beta, phosphorylated tau, Alzheimer's disease, neurodegeneration, brain atrophy, entorhinal cortex, hippocampus, cerebrospinal fluid biomarkers, mild cognitive impairment, cognitively normal older adults, amyloid-beta 42
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Female, Follow-Up Studies, Humans, Longitudinal Studies, Male, Peptide Fragments, Cohort Studies, Biomarkers, Amyloid beta-Peptides, Neurodegenerative Diseases, Clusterin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
